Intelligent glucose response type micro needle tube as well as preparation method and application thereof
By constructing an intelligent glucose-responsive microneedle tube, the cavity structure and glucose concentration response mechanism of the double crosslinked gel network are used to solve the safety problems caused by the dissolution of needle material in insulin microneedle injection treatment, achieving more efficient and Controllable insulin release.
Patent Information
- Application Number
- CN202411050735.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-01
AI Technical Summary
In the existing insulin microneedle injection treatment, the reactants, initiators and organic solvents of the needle material are easily dissolved, resulting in skin inflammation and safety problems.
Using intelligent glucose-responsive microneedle tubes, the cavity needle body based on a double crosslinked gel network is constructed to avoid dissolution of needle body material and regulate insulin release through glucose concentration response.
It improves the controllability of drug load and insulin release, improves the safety and intelligence of treatment, avoids the dissolution of needle materials in the skin, and achieves intelligent release of blood glucose concentration-dependent.
Smart Images

Figure CN119055578A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical material technology, and specifically relates to an intelligent glucose-responsive microneedle tube and a preparation method and application thereof. Background Art
[0002] Diabetes is a chronic disease caused by damage to the pancreas, which leads to long-term excessive and disordered blood sugar. For type 1 and severe type 2 diabetes, the only treatment is to supplement insulin in vitro to regulate blood sugar. The current conventional injection treatment has poor controllability of insulin release. Therefore, it is easy to cause hypoglycemia, and in severe cases, it can endanger the patient's life.
[0003] In order to improve the controllability and safety of insulin injection therapy, researchers have developed a microneedle delivery technology that responds to glucose concentration to enhance the intelligence of injection therapy. However, during microneedle therapy, the drug release process is often accompanied by the dissolution of the needle body material at the front end of the microneedle. The needle body material often contains reactants, initiators, and organic solvents added during the microneedle processing process. Therefore, the dissolution process of the needle body may also cause side effects such as inflammation of the skin in the treatment area. In response to this dissolution problem, the dissolution of the microneedle can be avoided to a great extent by constructing a composite cross-linking system in the microneedle gel matrix.
[0004] However, during the prior art insulin microneedle injection therapy, reactants, initiators and organic solvents in the needle body material are usually easily dissolved, causing potential safety issues such as skin inflammation and immunity. Summary of the invention
[0005] The present invention intends to solve the safety problems of potential skin inflammation and immunity caused by the dissolution of reactants, initiators and organic solvents in the needle body material during microneedle injection therapy. The present invention provides a smart glucose-responsive microneedle tube and its preparation method and application, which avoids the above problems by constructing a smart glucose-responsive cavity needle body based on a double cross-linked gel network.
[0006] The present invention can improve the drug loading and controllable insulin release performance by establishing an intelligent glucose-responsive microneedle tube. In addition, the cavity structure with an intelligent glucose-responsive mechanism can prevent the needle material from dissolving in the skin, thereby further improving the safety and intelligence of microneedle injection therapy.
[0007] The present invention can also realize blood glucose concentration-dependent insulin intelligent release by regulating the cross-linking sites of the glucose concentration response function in the gel. In addition, by adjusting the mixing ratio of the needle gel substrate components, drug-carrying cavity structures with different sizes can be customized.
[0008] The technical solution adopted by the present invention is:
[0009] 1. A smart glucose-responsive microneedle tube:
[0010] The microneedle tube is mainly composed of a needle body shell with a cavity structure and a drug component. The drug component is wrapped in the cavity structure of the needle body shell. The needle body shell with a cavity structure is mainly made of a mixed gel composed of modified polymers, and the drug component is a solid powder or a solution.
[0011] The modified polymer is mainly composed of modified ethylene glycol chitosan and modified oxidized dextran, namely, ethylene glycol chitosan grafted with phenylboronic acid and oxidized dextran grafted with dopamine. The mixed gel is the cross-linked hydrogel obtained by the preparation method.
[0012] The microneedle tube also includes a back patch, which is fixed on the surface of the needle body shell and is mainly made of a solution of natural polymer materials.
[0013] The needle shell with a cavity structure is based on cross-linked gel, which provides drug loading capacity and intelligent glucose response performance. The back patch is a natural polymer material that provides good biocompatibility and mechanical strength.
[0014] The drug components are specifically one or more of recombinant human insulin, insulin aspart, insulin glargine and glucagon-like polypeptide-1, and the added amount of the drug components is 0.5-100 IU.
[0015] The natural polymer material is specifically one or more of hyaluronic acid, collagen, gelatin and sodium alginate.
[0016] 2. A method for preparing an intelligent glucose-responsive microneedle tube, the method comprising:
[0017] 1) dissolving a compound containing phenylboronic acid groups, ethylene glycol chitosan, and a catalyst in a solvent to obtain respective solutions, and then mixing the three solutions to obtain ethylene glycol chitosan grafted with phenylboronic acid;
[0018] 2) dissolving dextran and sodium periodate in deionized water to obtain respective solutions, and then mixing the two solutions to prepare oxidized dextran;
[0019] 3) dissolving oxidized dextran and dopamine hydrochloride in deionized water to obtain respective solutions, and then mixing the two solutions to obtain oxidized dextran grafted with dopamine;
[0020] 4) dissolving the ethylene glycol chitosan grafted with phenylboronic acid prepared in step 1) and the oxidized dextran grafted with dopamine prepared in step 3) in deionized water respectively, and then mixing the two solutions to prepare a cross-linked hydrogel;
[0021] 5) The cross-linked hydrogel prepared in step 4) is injected into a microneedle mold for centrifugation and drying, and then the drug component is added thereto to prepare a drug-loaded needle body shell with a cavity structure, namely, a smart glucose-responsive microneedle tube.
[0022] Thus, through the above steps, the intelligent glucose-responsive microneedle tube is prepared.
[0023] In a specific implementation, a layer of natural polymer-based aqueous solution can be added to the back to form a back patch, and after drying again, a smart glucose-responsive microneedle tube can be prepared.
[0024] The back patch is formed by coating or spraying a natural polymer-based aqueous solution with a concentration of 300 mg / mL.
[0025] The step 1) specifically includes:
[0026] 1.1) dissolving a compound containing phenylboronic acid groups and ethylene glycol chitosan in a solvent to prepare a mixed solution A;
[0027] 1.2) dissolving the catalyst in a solvent to prepare a mixed solution B;
[0028] 1.3) Pour the mixed solution B into the mixed solution A and stir for a certain period of time to obtain a first reaction solution;
[0029] 1.4) The first reaction solution is dialyzed and freeze-dried in sequence to prepare ethylene glycol chitosan grafted with phenylboronic acid.
[0030] The step 1) may also be specifically as follows:
[0031] 1.1) dissolving the compound containing phenylboronic acid group, ethylene glycol chitosan and catalyst in solvents to form respective solutions;
[0032] 1.2) pouring the catalyst solution into the solution of the compound containing phenylboronic acid group, and then pouring into the ethylene glycol chitosan solution, and stirring the reaction for a certain time to obtain a first reaction solution;
[0033] 1.3) The first reaction solution is dialyzed and freeze-dried in sequence to prepare ethylene glycol chitosan grafted with phenylboronic acid.
[0034] In the step 1), the amount of the compound containing phenylboronic acid groups added is 0.01-6 g, the amount of ethylene glycol chitosan added is 0.01-6 g, the amount of the solvent used is 2-100 mL, the amount of the catalyst used is 20%-80% of the added mass of the compound containing phenylboronic acid groups, and the amount of the catalyst added is 0.002-4.8 g;
[0035] In the step 1), the compound containing a phenylboronic acid group is specifically one or more of 3-carboxyphenylboronic acid, 4-carboxyphenylboronic acid, 4-carboxyphenylboronic acid pinacol ester, 4-(carboxymethyl)phenylboronic acid pinacol ester and 4-carboxy-2-fluorophenylboronic acid pinacol ester; the catalyst specifically includes one or more of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride EDC and N-hydroxysuccinimide NHS; and the solvent is one or more of deionized water, methanol, isopropanol, anhydrous ethanol, dimethyl sulfoxide and N,N-dimethylformamide.
[0036] The solvents of the compound containing phenylboronic acid group, ethylene glycol chitosan and catalyst are the same.
[0037] The step 2) is specifically as follows:
[0038] 2.1) Dissolving dextran of different molecular weights in deionized water to prepare a mixed solution C;
[0039] 2.2) Dissolve sodium periodate in deionized water to prepare a mixed solution D;
[0040] 2.3) Pour the mixed solution D into the mixed solution C and stir for a certain period of time to obtain a second reaction solution;
[0041] 2.4) dialyzing and freeze-drying the second reaction solution in sequence to prepare oxidized dextran;
[0042] In the step 2), the molecular weight of dextran is 30,000 to 100,000, the amount of dextran added is 0.01-5g, and the amount of sodium periodate added is 0.01-5g.
[0043] The step 3) is specifically as follows:
[0044] 3.1) dissolving oxidized dextran in deionized water to prepare a mixed solution E;
[0045] 3.2) dissolving dopamine hydrochloride in deionized water to prepare a mixed solution F;
[0046] 3.3) Pour the mixed solution F into the mixed solution E and stir for a certain period of time to obtain a third reaction solution;
[0047] 3.4) dialyzing and freeze-drying the solution after the third reaction in sequence to prepare oxidized dextran grafted with dopamine;
[0048] In the step 3), the amount of oxidized dextran added is 0.01-5g, and the amount of dopamine hydrochloride added is 0.01-5g.
[0049] In the steps 1), 2) and 3), the reaction temperature is 5-25° C. and the reaction time is 1-48 hours; preferably, the reaction time is 1-12 hours.
[0050] In the step 4), the concentration of the aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid is 5-500 mg / mL, the concentration of the aqueous solution of oxidized dextran grafted with dopamine is 5-500 mg / mL, and the volume ratio of the two solutions is 1:3 to 3:1;
[0051] In the step 4), the centrifugation process is specifically centrifuging at a centrifugal speed of 500-4000 rpm for 10-30 minutes; the drying process is specifically placing the microneedle mold in a dryer for 6-48 hours, and the drying environment is 10% humidity and 25° C. The two drying processes are the same.
[0052] The intelligent glucose-responsive microneedle tube of the present invention is used in diabetes medicine, specifically in the preparation and release of insulin drugs.
[0053] The intelligent glucose-responsive microneedle tube of the present invention adjusts the concentration and addition amount relationship between the ethylene glycol chitosan grafted with phenylboronic acid and the oxidized dextran grafted with dopamine, thereby regulating the crosslinking density and solid content of the crosslinked hydrogel as the needle gel substrate, thereby adjusting the insulin loading amount, and at the same time adjusting the sugar-sensitive swelling properties of the needle shell, and intelligently regulating the release of insulin. Specifically, when the insulin concentration is higher, it will autonomously regulate the release of more insulin.
[0054] The smart glucose-responsive microneedle tube described in the present invention can customize the insulin loading amount by adjusting the crosslinking density and solid content of the needle gel substrate. And through the sugar-sensitive swelling properties of the cavity needle body, the insulin release process can be intelligently regulated. In the in vitro swelling and release test, the microneedle exhibited stable swelling properties and excellent sugar-sensitive release characteristics.
[0055] The microneedle tube of the present invention comprises a needle body shell with a cavity structure, a drug component and a back patch. The needle body shell with a cavity structure is prepared by a mixed gel of ethylene glycol chitosan modified by phenylboronic acid and oxidized dextran grafted with dopamine through a molding method. The drug component is insulin powder, which is directly loaded into the needle body shell with a cavity structure to complete the drug loading step.
[0056] The back patch is prepared by using an aqueous solution of hyaluronic acid as a substrate. The microneedle tube has the ability to release drugs in an intelligent response to glucose concentration, and can achieve effective skin puncture and long-term drug release effects.
[0057] The smart glucose-responsive microneedle tube prepared by the present invention can customize the size of the microneedle drug-carrying cavity and improve the drug-carrying efficiency. At the same time, the release rate and duration of the drug can be customized to meet the treatment needs by adjusting the cross-linking degree and solid content of the mixed gel. The microneedle improves the safety of microneedle treatment through a stable and controllable glucose concentration-responsive swelling mechanism.
[0058] The beneficial effects of the present invention are:
[0059] 1. The microneedle tube of the present invention has a cavity structure, which can increase the drug loading capacity. And by adjusting the cross-linking density and solid content in the needle gel matrix, the drug loading capacity can be customized.
[0060] 2. The microneedle tube of the present invention has sensitive and long-lasting glucose concentration response characteristics. Through the intelligent glucose response behavior of the needle body, the insulin loaded therein is released in a glucose-sensitive manner. The microneedle tube also has good mechanical strength and skin puncture efficiency.
[0061] 3. The microneedle tube substrate of the present invention has good biocompatibility, and avoids the side effects of the dissolution of the needle material on the human body by the swelling release mechanism, further improving the safety of treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 The optical microscope images of the needle body shell with a cavity structure of the present invention are shown in Figure (a), Figure (b), and Figure (c). The cavity structures in Figure (a), Figure (b), and Figure (c) decrease in sequence.
[0063] Figure 2 The present invention is a scanning electron microscope image of a needle body shell with a cavity structure, wherein (a) is a microneedle tube array, (b) is a top view of a microneedle tube, (c) is a side view of a microneedle tube, and (d) is a top view of a single microneedle tube;
[0064] Figure 3 This is a graph showing the results of an in vitro glucose-sensitive swelling test of the microneedle tube of the present invention;
[0065] Figure 4 The in vitro glucose-sensitive release test results of the microneedle tube of the present invention are shown in Figure (a) for the cumulative release under three glucose concentration environments, and Figure (b) for the alternating release under a gradient glucose concentration environment;
[0066] Figure 5 The biocompatibility test results of the microneedle tube substrate of the present invention are shown in Figure (a) for the hemolytic test and Figure (b) for the cytotoxicity test;
[0067] Figure 6 This is a graph showing the pig skin puncture test results of the microneedle tube of the present invention. DETAILED DESCRIPTION
[0068] The present invention is described in more detail below in conjunction with the accompanying drawings and embodiments, but the present invention is not limited thereto. For those skilled in the art, several improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications are also considered to be within the scope of protection of the present invention. The contents not described in detail in this specification belong to the prior art known to professional and technical personnel in the field.
[0069] The specific embodiments of the present invention are as follows:
[0070] Embodiment 1:
[0071] 1) Dissolve 0.5694g of 3-carboxyphenylboronic acid in 20mL of dimethyl sulfoxide (DMSO) to prepare a DMSO solution of 3-carboxyphenylboronic acid. Dissolve 0.5965g of ethylene glycol chitosan in 50mL of deionized water to prepare an ethylene glycol chitosan aqueous solution. Dissolve 0.2855g of EDC and 0.1896g of NHS in 10mL of deionized water to prepare an aqueous catalyst solution. Slowly pour the aqueous catalyst solution into the DMSO solution of 3-carboxyphenylboronic acid, then slowly add the ethylene glycol chitosan aqueous solution thereto, and react at 25°C for 6h. The reaction solution is dialyzed in deionized water for three days, and ethylene glycol chitosan grafted with phenylboronic acid is prepared after freeze-drying.
[0072] 2) Dissolve 1.8963 g of 30,000 molecular weight dextran in 20 mL of deionized water to prepare a dextran aqueous solution. Dissolve 0.9563 g of sodium periodate in 20 mL of deionized water to prepare a sodium periodate aqueous solution. Slowly pour the sodium periodate aqueous solution into the dextran aqueous solution and react at 25° C. for 5 h. The reaction solution is dialyzed in deionized water for three days and freeze-dried to obtain oxidized dextran.
[0073] 3) Dissolve 0.9638 g of the prepared oxidized dextran in 10 mL of deionized water to prepare an oxidized dextran aqueous solution. Dissolve 1.2589 g of dopamine hydrochloride in 20 mL of deionized water to prepare an aqueous dopamine hydrochloride solution. Slowly pour the dopamine hydrochloride aqueous solution into the oxidized dextran aqueous solution, introduce nitrogen and react at 25° C. for 10 h. The reaction solution is dialyzed in deionized water for three days, and freeze-dried to prepare oxidized dextran grafted with dopamine.
[0074] 4) Dissolve the ethylene glycol chitosan grafted with phenylboronic acid obtained in step 1) in deionized water to prepare an aqueous solution of 10 mg / mL ethylene glycol chitosan grafted with phenylboronic acid. Dissolve the oxidized dextran grafted with dopamine obtained in step 3) in deionized water to prepare an aqueous solution of 50 mg / mL oxidized dextran grafted with dopamine, take 100 μL of the aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid and 100 μL of the aqueous solution of oxidized dextran grafted with dopamine, and mix them to prepare a cross-linked hydrogel. While keeping the total volume of the mixed solution at 200 μL unchanged, 75 μL of an aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid and 125 μL of an aqueous solution of oxidized dextran grafted with dopamine were mixed; or 125 μL of an aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid and 75 μL of an aqueous solution of oxidized dextran grafted with dopamine were mixed to prepare hydrogels with different solid contents and crosslinking densities.
[0075] 5) The cross-linked hydrogel prepared in step 4) was injected into the microneedle mold, centrifuged at 4000 rpm for 10 minutes, and then placed in a dryer at 25°C and 10% humidity for 12 hours. After that, 5, 10 and 15 IU of insulin powder were added to the mold according to the size of the cavity volume, and 100 μL of 300 mg / mL hyaluronic acid aqueous solution was added to the back. It was placed in a dryer at 25°C and 10% humidity for 12 hours to prepare needles with different cavity structures and different drug loadings.
[0076] 6) Observe the prepared microneedle tube using an optical microscope. Figure 1 As shown, the microneedle tube has an obvious cavity structure represented by the dotted line. In the experiment, the addition and mixing ratio of the two modified polymer solutions in the gel were regulated to form a mixed gel system with different concentrations of cross-linking sites. By adjusting the cross-linking density and solid content, cavity structures of different sizes can be formed after drying. Figure 1 The cavity structures in (a)-(c) have regular volume changes, and this cavity structure can directly load and store drug powder. Compared with microneedles loaded with solvent-based drugs, its drug loading efficiency is greatly improved. In addition, by designing the cavity size, intelligent quantitative loading of drugs can be achieved.
[0077] The microneedle structure was observed by scanning electron microscopy. Figure 2 As shown, it is confirmed that the prepared microneedle tube has a good microneedle array arrangement and a complete needle body structure.
[0078] Embodiment 2:
[0079] 1) Dissolve 0.7963g of 3-carboxyphenylboronic acid in 25mL of dimethyl sulfoxide (DMSO) to prepare a DMSO solution of 3-carboxyphenylboronic acid. Dissolve 0.6262g of ethylene glycol chitosan in 50mL of deionized water to prepare an ethylene glycol chitosan aqueous solution. Dissolve 0.3696g of EDC and 0.3578g of NHS in 10mL of deionized water to prepare an aqueous catalyst solution. Slowly pour the aqueous catalyst solution into the DMSO solution of 3-carboxyphenylboronic acid, then slowly add the ethylene glycol chitosan aqueous solution thereto, and react at 25°C for 12h. The reaction solution is dialyzed in deionized water for three days, and ethylene glycol chitosan grafted with phenylboronic acid is prepared after freeze-drying.
[0080] 2) Dissolve 1.6396 g of 50,000 molecular weight dextran in 20 mL of deionized water to prepare a dextran aqueous solution. Dissolve 0.8822 g of sodium periodate in 15 mL of deionized water to prepare a sodium periodate aqueous solution. Slowly pour the sodium periodate aqueous solution into the dextran aqueous solution and react at 25° C. for 10 h. The reaction solution is dialyzed in deionized water for three days and freeze-dried to obtain oxidized dextran.
[0081] 3) Dissolve 0.9999 g of the prepared oxidized dextran in 15 mL of deionized water to prepare an oxidized dextran aqueous solution. Dissolve 1.3693 g of dopamine hydrochloride in 25 mL of deionized water to prepare an aqueous dopamine hydrochloride solution. Slowly pour the dopamine hydrochloride aqueous solution into the oxidized dextran aqueous solution, introduce nitrogen and react at 25° C. for 8 h. The reaction solution is dialyzed in deionized water for three days, and freeze-dried to prepare oxidized dextran grafted with dopamine.
[0082] 4) Dissolve the ethylene glycol chitosan grafted with phenylboronic acid obtained in step 1) in deionized water to prepare an aqueous solution of 50 mg / mL ethylene glycol chitosan grafted with phenylboronic acid. Dissolve the oxidized dextran grafted with dopamine obtained in step 3) in deionized water to prepare an aqueous solution of 100 mg / mL oxidized dextran grafted with dopamine, take 100 μL of the aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid and 200 μL of the aqueous solution of oxidized dextran grafted with dopamine and mix them to prepare a cross-linked hydrogel.
[0083] 5) The cross-linked hydrogel prepared in step 4) was injected into the microneedle mold, centrifuged at 3000 rpm for 20 minutes, and then placed in a dryer at 25°C and 10% humidity for 12 hours. After that, 20 IU of insulin powder was added thereto, and 100 μL of 300 mg / mL hyaluronic acid aqueous solution was added to the back. It was placed in a dryer at 25°C and 10% humidity for 24 hours to prepare a drug-loaded needle body shell with a cavity structure.
[0084] 6) The prepared microneedle tube was subjected to an in vitro glucose-sensitive swelling test. Figure 3 As shown, the microneedle tubes were placed in different glucose environment concentrations of 0 mg / mL, 100 mg / mL, and 400 mg / mL, and the morphology of the microneedle tubes was recorded at 6 h and 12 h. It can be seen that the microneedle tubes will undergo more obvious swelling behavior in a higher glucose concentration environment, and the structure of the microneedle tubes continues to remain intact during this process. The above experiments confirm the swelling release mechanism of the microneedle. Different from the dissolving microneedle, this microneedle tube avoids the potential immune rejection and other side effects of the body after the dissolution of the microneedle substrate, delivers drugs in a safer way, and also reduces the treatment risk in long-term drug delivery.
[0085] Embodiment 3:
[0086] 1) Dissolve 1.3569g of 3-carboxyphenylboronic acid in 45mL of dimethyl sulfoxide (DMSO) to prepare a DMSO solution of 3-carboxyphenylboronic acid. Dissolve 1.1715g of ethylene glycol chitosan in 60mL of deionized water to prepare an ethylene glycol chitosan aqueous solution. Dissolve 0.9869g of EDC and 0.8698g of NHS in 20mL of deionized water to prepare an aqueous catalyst solution. Slowly pour the aqueous catalyst solution into the DMSO solution of 3-carboxyphenylboronic acid, then slowly add the ethylene glycol chitosan aqueous solution thereto, and react at 25°C for 8h. The reaction solution is dialyzed in deionized water for three days, and ethylene glycol chitosan grafted with phenylboronic acid is prepared after freeze-drying.
[0087] 2) Dissolve 1.2145 g of 100,000 molecular weight dextran in 20 mL of deionized water to prepare a dextran aqueous solution. Dissolve 0.7896 g of sodium periodate in 15 mL of deionized water to prepare a sodium periodate aqueous solution. Slowly pour the sodium periodate aqueous solution into the dextran aqueous solution and react at 25° C. for 6 hours. The reaction solution is dialyzed in deionized water for three days and freeze-dried to obtain oxidized dextran.
[0088] 3) Dissolve 0.6939 g of the prepared oxidized dextran in 12 mL of deionized water to prepare an oxidized dextran aqueous solution. Dissolve 1.1515 g of dopamine hydrochloride in 18 mL of deionized water to prepare an aqueous dopamine hydrochloride solution. Slowly pour the dopamine hydrochloride aqueous solution into the oxidized dextran aqueous solution, introduce nitrogen and react at 25° C. for 9 h. The reaction solution is dialyzed in deionized water for three days, and freeze-dried to prepare oxidized dextran grafted with dopamine.
[0089] 4) Dissolve the ethylene glycol chitosan grafted with phenylboronic acid obtained in step 1) in deionized water to prepare an aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid at a concentration of 90 mg / mL. Dissolve the oxidized dextran grafted with dopamine obtained in step 3) in deionized water to prepare an aqueous solution of oxidized dextran grafted with dopamine at a concentration of 90 mg / mL, take 100 μL of the aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid and 300 μL of the aqueous solution of oxidized dextran grafted with dopamine and mix them to prepare a cross-linked hydrogel.
[0090] 5) The cross-linked hydrogel prepared in step 4) was injected into the microneedle mold, centrifuged at 4000 rpm for 25 minutes, and then placed in a dryer at 25°C and 10% humidity for 24 hours. After that, 15 IU of insulin powder was added thereto, and 100 μL of a 300 mg / mL gelatin aqueous solution was added to the back. It was placed in a dryer at 25°C and 10% humidity for 12 hours to prepare a drug-loaded needle body shell with a cavity structure.
[0091] 6) The prepared microneedle tube was subjected to an in vitro glucose-sensitive release test. Figure 4 As shown, the insulin-loaded microneedle tubes were placed in different glucose environment concentrations of 0 mg / mL, 100 mg / mL, and 400 mg / mL for drug release testing. Figure 4 As shown in (a), the difference in insulin release from the microneedle tube within the release time of 16 hours is determined by the glucose concentration in the external environment. The release amount is the largest at a glucose concentration of 400 mg / mL, and the cumulative amount reaches 16.1%. In the first 4 hours of release, the release rate of the microneedle tube is relatively large; the release rate slowly decreases from 4 to 16 hours, indicating that the cross-linked structure inside the gel will continuously establish a new equilibrium system during the sugar-sensitive release process, and can continue to maintain the release difference under different glucose concentration environments. It can be inferred that this microneedle tube can release drugs and exert therapeutic effects over a longer period of time. Figure 4 As shown in (b), the release test in a gradient glucose concentration environment showed a glucose concentration-dependent release rate difference. The release rate at 400 mg / mL glucose concentration was significantly higher than that at 400 mg / mL glucose concentration, which further highlighted the glucose sensitivity recognition and release sensitivity of the microneedle tube in a changing glucose concentration environment. In summary, the microneedle tube showed good glucose sensitivity and long-term potential for controlling insulin release in the in vitro glucose sensitivity test.
[0092] 7) The prepared microneedle tube substrate is subjected to cytotoxicity test and hemolytic test. Figure 5 As shown, Figure 5 (a) It was confirmed that the substrate of the microneedle tube had no significant cytotoxicity and would not inhibit the normal growth and reproduction of cells. Figure 5 (b) It is confirmed that the base material of the microneedle tube has good blood compatibility.
[0093] like Figure 6 As shown, the prepared microneedle tube has excellent skin piercing performance. Figure 6 (a) with Figure 6 (c) Clear puncture marks left by the microneedle tube on the pig skin can be found, and each dark site represents a tiny cavity mark left by the microneedle during the puncture process. Figure 6 (d) After puncturing the pig skin with alcohol cleaning, the corresponding sites left by the microneedle tube on the skin can still be found, confirming that this microneedle tube has a high skin puncture efficiency.
[0094] It can be seen from the above embodiments that the present invention provides an intelligent glucose-responsive microneedle tube and its preparation method and application. The intelligent glucose-responsive microneedle tube of the present invention can obtain a cavity structure with a customizable size by adjusting the cross-linking degree and solid content of the microneedle substrate cross-linked hydrogel, thereby realizing a customized design of the drug loading amount. This microneedle tube releases insulin in a sugar-sensitive swelling manner, reducing the immune rejection caused by the dissolution of the microneedle body. In addition, this microneedle tube regulates the sugar-sensitive response process with the synergistic effect of multiple cross-linking to achieve a more lasting release effect, thereby achieving a safe, long-term, intelligent blood sugar control effect.
Claims
1. An intelligent glucose-responsive microneedle tube, characterized in that: The microneedle tube is mainly composed of a needle body shell with a cavity structure and a drug component. The drug component is wrapped in the cavity structure of the needle body shell. The needle body shell with a cavity structure is mainly made of a mixed gel composed of modified polymers, and the drug component is a solid powder or a solution.
2. The smart glucose-responsive microneedle tube according to claim 1, characterized in that: The modified polymer is mainly composed of modified ethylene glycol chitosan and modified oxidized dextran.
3. The smart glucose-responsive microneedle tube according to claim 1, characterized in that: The microneedle tube also includes a back patch, which is fixed on the surface of the needle body shell and is mainly made of a solution of natural polymer materials.
4. The method for preparing the smart glucose-responsive microneedle tube according to any one of claims 1 to 3, characterized in that the method include: 1) dissolving a compound containing phenylboronic acid groups, ethylene glycol chitosan, and a catalyst in a solvent to obtain respective solutions, and then mixing the three solutions to obtain ethylene glycol chitosan grafted with phenylboronic acid; 2) dissolving dextran and sodium periodate in deionized water to obtain respective solutions, and then mixing the two solutions to prepare oxidized dextran; 3) dissolving oxidized dextran and dopamine hydrochloride in deionized water to obtain respective solutions, and then mixing the two solutions to obtain oxidized dextran grafted with dopamine; 4) dissolving the ethylene glycol chitosan grafted with phenylboronic acid prepared in step 1) and the oxidized dextran grafted with dopamine prepared in step 3) in deionized water respectively, and then mixing the two solutions to prepare a cross-linked hydrogel; 5) The cross-linked hydrogel prepared in step 4) is injected into a microneedle mold for centrifugation and drying, and then the drug component is added to prepare a drug-loaded needle body shell with a cavity structure, that is, a smart glucose-responsive microneedle tube.
5. The method for preparing the smart glucose-responsive microneedle tube according to claim 4, characterized in that: In the step 1), the amount of the compound containing phenylboronic acid groups added is 0.01-6 g, the amount of ethylene glycol chitosan added is 0.01-6 g, the amount of the solvent used is 2-100 mL, the amount of the catalyst used is 20%-80% of the added mass of the compound containing phenylboronic acid groups, and the amount of the catalyst added is 0.002-4.8 g; In the step 1), the compound containing a phenylboronic acid group is specifically one or more of 3-carboxyphenylboronic acid, 4-carboxyphenylboronic acid, 4-carboxyphenylboronic acid pinacol ester, 4-(carboxymethyl)phenylboronic acid pinacol ester and 4-carboxy-2-fluorophenylboronic acid pinacol ester; the catalyst specifically includes one or more of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride EDC and N-hydroxysuccinimide NHS; and the solvent is one or more of deionized water, methanol, isopropanol, anhydrous ethanol, dimethyl sulfoxide and N,N-dimethylformamide.
6. The method for preparing the smart glucose-responsive microneedle tube according to claim 4, characterized in that: The step 2) is specifically as follows: 2.1) Dissolving dextran of different molecular weights in deionized water to prepare a mixed solution C; 2.2) Dissolve sodium periodate in deionized water to prepare a mixed solution D; 2.3) Pour the mixed solution D into the mixed solution C, and stir to react to obtain a second reacted solution; 2.4) dialyzing and freeze-drying the second reaction solution in sequence to prepare oxidized dextran; In the step 2), the molecular weight of dextran is 30,000 to 100,000, the amount of dextran added is 0.01-5g, and the amount of sodium periodate added is 0.01-5g.
7. The method for preparing the smart glucose-responsive microneedle tube according to claim 4, characterized in that: The step 3) is specifically as follows: 3.1) dissolving oxidized dextran in deionized water to prepare a mixed solution E; 3.2) dissolving dopamine hydrochloride in deionized water to prepare a mixed solution F; 3.3) Pour the mixed solution F into the mixed solution E and stir to react to obtain a third post-reaction solution; 3.4) dialyzing and freeze-drying the solution after the third reaction in sequence to prepare oxidized dextran grafted with dopamine; In the step 3), the amount of oxidized dextran added is 0.01-5g, and the amount of dopamine hydrochloride added is 0.01-5g.
8. The method for preparing the smart glucose-responsive microneedle tube according to claim 4, characterized in that: In the steps 1), 2) and 3), the reaction temperature is 5-25° C. and the reaction time is 1-48 hours; In the step 4), the concentration of the aqueous solution of ethylene glycol chitosan grafted with phenylboronic acid is 5-500 mg / mL, the concentration of the aqueous solution of oxidized dextran grafted with dopamine is 5-500 mg / mL, and the volume ratio of the two solutions is 1:3 to 3:1; In the step 4), the centrifugation process is specifically centrifuging at a centrifugal speed of 500-4000 rpm for 10-30 minutes; the drying process is specifically placing the microneedle mold in a dryer and drying it for 6-48 hours.
9. Use of the smart glucose-responsive microneedle tube according to any one of claims 1 to 3 or the smart glucose-responsive microneedle tube prepared by the preparation method according to any one of claims 4 to 8, characterized in that: Application in diabetes medicine.
10. A method for regulating insulin loading and release using the smart glucose-responsive microneedle tube according to any one of claims 1 to 3 or the smart glucose-responsive microneedle tube prepared by the preparation method according to any one of claims 4 to 8, characterized in that: By adjusting the concentration and addition amount relationship between ethylene glycol chitosan grafted with phenylboronic acid and oxidized dextran grafted with dopamine, the cross-linking density and solid content of the cross-linked hydrogel can be regulated, thereby adjusting the insulin loading amount. At the same time, the sugar-sensitive swelling properties of the needle shell are adjusted to intelligently regulate the release of insulin.
Citation Information
Patent Citations
Preparation and application of pH glucose dual sensitive hydrogel
CN104758939A
Glucose sensitive porous microsphere / polymer composite gel as well as preparation method and application thereof
CN106038478A
Silver-containing hydrogel as well as preparation method and application thereof
CN112979995A
Core-shell structure sugar-sensitive microneedle patch based on cross-linking density variable sugar-sensitive film and preparation method of core-shell structure sugar-sensitive microneedle patch
CN115869241A
Intelligent hydrogel as well as preparation method and application thereof
CN116672494A
